Expiration date: 11/2027

Form of release

Tablets for resorption - 100 pcs. in the box

Dosage form

Tablets are flat-cylindrical in shape, with a risk and a chamfer, from white to almost white in color. The inscription MATERIA MEDICA is printed on the flat side with a risk.

Composition

Active substance:

Antibodies to the brain-specific protein S-100 affinity purified, modified - 10,000 EMD*.

Excipients: lactose monohydrate (lactose), microcrystalline cellulose, magnesium stearate.

* EMD - units of modifying action.

Pharmacotherapeutic group

nootropic agent

Pharmacodynamics

By modifying the functional activity of the brain-specific protein S-100, the drug improves the integrative activity of the brain at all levels of the organization of neural systems (cellular, intercellular, structural and systemic).

Protein S-100 is widely represented in the central nervous system and belongs to the family of Ca2+-binding proteins. The protein regulates the following fundamental processes in the brain: generation and conduction of nerve impulses, synaptic signal transmission; stimulation of differentiation and proliferation of neurons; at the systemic level, protein S-100 modifies the ratio of activation and inhibition processes, positively influencing the integrative activity of the brain. Due to this, S-100 has nootropic, neuroprotective and neurotrophic effects.

It has been experimentally shown that the drug:

• exhibits nootropic activity by improving the formation of a memory footprint based on the conditioned reflex amnesia model; compensating for age-related weakening of short-term memory mechanisms; enhancing long-term synaptic plasticity (the basis of cellular mechanisms of memory and learning);
• normalizes the emotional state and behavior in animals (reduces somatovegetative manifestations of stress, restores locomotor and research activity).

It has also been shown that the drug has neuroprotective and neuro-therapeutic effects: it increases the resistance of brain tissues to hypoxia and toxic effects, has a membrane-stabilizing, antioxidant effect. In the post-stroke or post-traumatic period, it mobilizes intracellular compensatory reserves of damaged and healthy neurons, as well as glial cells located in the damaged area, functionally coupled with the S-100 protein. It has a moderate anxiolytic effect (eliminates anxiety).

By changing the bioelectric activity of the brain, it can affect the structure of sleep.

Mechanism of action

Studies on cell membranes expressing human GABA, serotonin, and dopamine receptors (GABA1A/B2, 5-HT2B, 5-HT2C, 5-HT3, and D3, respectively) have shown that the drug increases the number of ligand-receptor complexes, meaning it can affect both inhibitory and inhibitory effects. activating neurotransmitter systems. By normalizing the balance of levels of the main neurotransmitters, the drug supports the integrative activity of the brain.

A change in the spectral power of the bioelectric activity of the cerebral cortex, hippocampus and hypothalamus under the action of the Prospectus has been experimentally demonstrated.

The nootropic effect of the drug has been proven in a clinical study on the treatment of patients in the early recovery period of ischemic stroke. The patients' cognitive functions improved according to the Montreal Cognitive Assessment Scale (MoCA), which evaluates various cognitive areas (attention and concentration, executive functions, memory, language, visual-constructive skills, abstract thinking, counting and orientation). There was a recovery in activity in daily life according to the Bartel scale, which evaluates such areas of activity as the ability to eat, take care of oneself, including showering and dressing, physiological functions (stool, urination), the ability to move (from bed to chair and back), mobility on a flat surface and climbing stairs. According to testing on the stroke quality of life Assessment scale (SS-QOL), patients showed improvement in most indicators (speech, vision, thinking, mood, mobility, etc.). Normalization of patients' behavior and mood manifested itself in the form of a decrease in irritability, an increase in the level of self-care, a decrease in difficulties with doing daily housework, and an increase in the social role in the family.

Pharmacokinetics

The sensitivity of modern physico-chemical analysis methods (gas-liquid chromatography, high-performance liquid chromatography, chromato-mass spectrometry) does not allow us to assess the content of the active substance of the drug Prospect in biological fluids, organs and tissues due to the specific composition of the drug (see the section "Composition"), which makes it technically impossible to study the pharmacokinetics.

Indications

The drug Prospectus is indicated for use in adults

Cognitive impairments of various origins, including after acute cerebral circulatory disorders.

Contraindications

Increased individual sensitivity to the components of the drug. Children under the age of 18.

Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.

Use during pregnancy and lactation

The safety of using the Prospectus in pregnant women and during breastfeeding has not been studied. If necessary, the risk /benefit ratio should be taken into account.

Method of administration and dosage

Riska is not intended to divide the tablet into parts.

Inside. Take 2 tablets at a time (keep in mouth until completely dissolved - not during meals). Take it 2 times a day. The course of treatment is 6 months; if necessary, the course of treatment can be repeated in 1-2 months.

If there is no improvement in the condition within 4 weeks after the start of treatment, it is necessary to consult a doctor.

Side effects

Reactions of increased individual sensitivity to the components of the drug are possible.

In rare cases, the drug may cause drowsiness.

Overdose

In case of overdose, dyspeptic phenomena are possible due to the excipients included in the preparation.

Drug interaction

To date, no cases of incompatibility with other medicines have been reported.

Special conditions

The drug contains lactose, and therefore it is not recommended to prescribe it to patients with congenital galactosemia, glucose or galactose malabsorption syndrome, or with congenital lactase deficiency.

Impact on the ability to drive vehicles

Drowsiness may occur in rare cases, so caution should be exercised when driving vehicles.

Storage temperature

from 2℃ to 25℃